Navigation Links
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Date:7/18/2013

SOUTH SAN FRANCISCO, Calif., July 18, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases. 

Several new investors participated in the Series C financing, including the Topspin Fund, an investment group comprised of James Simons, Leo A. Guthart, Andy Gyenes and Steven Winick.  The financing also included participation from our existing investors, including The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures.  With the Series C financing, NGM has raised over $130 million since the company's founding in 2008.

"With this $50 million round of equity financing, coupled with non-dilutive capital from our collaborations with Daiichi Sankyo, Janssen, MedImmune and JDRF, NGM is well-positioned to advance the promising pipeline of candidates generated by our drug discovery efforts," said William J. Rieflin, Chief Executive Officer of NGM.  "We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases.  NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.  For more information, please visit the company's website at www.ngmbio.com.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... NASHVILLE, Tenn. (PRWEB) , ... September 11, 2019 ... ... addition of Jeff Maris to lead its Cerner Strategic Implementation and Partnerships ... delivery as a Technology Sales Executive who expanded Cerner’s CareAware business and as ...
(Date:9/9/2019)... ... September 09, 2019 , ... New ... Dental Implants host the latest course in their Synergy Study Club, called “Truth ... features guest speaker Dr. Peter Barndt. Synergy Study Club brings together leading specialists ...
(Date:9/9/2019)... ... 09, 2019 , ... Dr. Jin Kim of Garden Grove, ... in Tilburg, Netherlands. A dual-board certified periodontist, Dr. Kim spoke about the application ... periodontics. At his practices in Diamond Bar and Garden Grove, CA, Dr. Kim ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... September 11, 2019 , ... RMA of Connecticut , ... their family, will host a free informational event that will demystify fertility age-related issues ... voucher for the first fifty registrants. The event, “What’s Your Real Fertility Age,” will ...
(Date:9/11/2019)... ... , ... Executives at health systems and hospitals across America are facing some ... past several years has been intense. For professionals and organizations that struggle with change, ... depend largely on how these executives respond. Will they have the tools they need ...
(Date:9/11/2019)... NEW YORK (PRWEB) , ... ... ... expertise of industry leaders to explore solutions to problems facing the ever-changing ... edition of their campaign, “Employee Benefits and Engagement.” With topics ranging from ...
(Date:9/9/2019)... ... September 09, 2019 , ... Drs. Steven White, Brad ... now welcome individuals with tooth loss in Davidson, NC who are seeking permanent ... single or multiple missing teeth and want the advantages of dental implants ...
(Date:9/9/2019)... RALEIGH, N.C. (PRWEB) , ... September 09, 2019 ... ... Directors voted unanimously to adopt an organization-wide policy focusing on a diabetes-language movement ... on language that is neutral and non-judgmental, free from stigma, respectful and inclusive, ...
Breaking Medicine News(10 mins):